Genentech Logo
Banner Image
Banner Image

Media

Newsroom

The Media section provides reporters with easy access to Genentech information for stories in development. It also houses our recent and archived press releases.

Alert Genentech Statements on Counterfeit Drug Labeled as Avastin® (bevacizumab) in the United States

Roche and Genentech have been informed by the FDA that counterfeit products, labeled as Avastin (bevacizumab) or Altuzan (bevacizumab), the brand name Roche sells Avastin under in Turkey, have been distributed illegally in the United States. Please see below for more information.

Read the statement from April 4, 2012 regarding Altuzan

Read the statement from February 14, 2012

News Events

Landmark Alzheimer's Prevention Trial
Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history. Learn more

Genentech Medicine Approved For Advanced Basal Cell Carcinoma
On January 30, 2012, the FDA approved a Genentech medicine for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. View information and materials on the approval

Genentech Medicine Approved For Certain Type Of Melanoma
On August 17, 2011, the FDA approved a Genentech medicine for a type of inoperable and metastatic melanoma. View information and materials on the approval


Recent Press Releases

May 15, 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012

May 2, 2012
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection

Mar 29, 2012
Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer

Mar 1, 2012
Genentech's ACTEMRA® Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy


MEDIA INQUIRIES

If you are a member of the media, please call our Corporate Relations department.

Corporate Relations: (650) 467-6800

SIGN UP FOR GENENTECH NEWS

Receive e-mail alert messages whenever a new press release is posted to this site.

FOLLOW GENENTECH ON TWITTER

Twitter LogoFollow Genentech on Twitter to receive the latest news and updates about the company.

NEWSROOM FEEDBACK

Please take a moment to fill out our .